Paula E. Keating

Christchurch, CAN, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

A novel case of autosomal recessive CARD11 loss-of-function underlying impaired antiviral immunity and a review of literature.

A novel case of autosomal recessive CARD11 loss-of-function underlying impaired antiviral immunity and a review of literature.

Journal: Clinical & translational immunology

Published: October 04, 2025

Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa/New Zealand.

Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa/New Zealand.

Journal: Rheumatology (Oxford, England)

Published: January 23, 2024

Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand.

Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand.

Journal: Seminars in arthritis and rheumatism

Published: January 07, 2024

Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant-activating mutation.

Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant-activating mutation.

Journal: Clinical & translational immunology

Published: January 05, 2024

Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study.

Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study.

Journal: The Journal of rheumatology

Published: December 19, 2023

Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.

Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.

Journal: Therapeutic drug monitoring

Published: August 02, 2023

Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.

Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.

Journal: Internal medicine journal

Published: June 07, 2023

Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study.

Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study.

Journal: Pathology

Published: May 04, 2022

HMGCR autoantibody testing: two tiers required.

HMGCR autoantibody testing: two tiers required.

Journal: Pathology

Published: November 01, 2020

Accurate Measurement of Adalimumab Using Competitive Homogeneous Mobility Shift Assay.

Accurate Measurement of Adalimumab Using Competitive Homogeneous Mobility Shift Assay.

Journal: Therapeutic drug monitoring

Published: October 03, 2020

A distinctive staining pattern with anti-3-hydroxy-3-methyl-glutaryl-coenzyme a reductase (HMGCR) antibodies on mouse kidney.

A distinctive staining pattern with anti-3-hydroxy-3-methyl-glutaryl-coenzyme a reductase (HMGCR) antibodies on mouse kidney.

Journal: Pathology

Published: April 13, 2020

Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay.

Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay.

Journal: Pathology

Published: October 08, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026